Venous Thromboembolism
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
News from the FDA/CDC
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
From the Journals
Older IBD patients are most at risk of postdischarge VTE
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
Conference Coverage
Researchers combine genetic and clinical factors in new VTE risk score
MELBOURNE – A score that combines both genetic and clinical risk factors for VTE in patients with lymphoma may offer a better option than current...
Conference Coverage
No reduction in PE risk with vena cava filters after severe injury
MELBOURNE – “Given the cost and risks associated with a vena cava filter, our data suggest that there is no urgency to insert the filter in...
Conference Coverage
Rivaroxaban tied to higher GI bleeding than other NOACs
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.
Conference Coverage
Occurrence of pulmonary embolisms in hospitalized patients nearly doubled during 2004-2015
NEW ORLEANS – National Inpatient Sample data showed that during 2004-2015 hospitalized U.S. patients with a PE diagnosis jumped by 80%.
From the Journals
Algorithm ruled out PE, averts radiation exposure in pregnant women
Only one deep-vein thrombosis and no pulmonary embolism occurred in 3 months of follow-up in nearly 500 women.
Video
AUGUSTUS: Dual surpasses triple therapy when AFib patients have PCI or ACS
NEW ORLEANS – Dropping aspirin but keeping anticoagulation with apixaban and antiplatelet clopidogrel was effective and associated with less...
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...